Group items matching

in title, tags, annotations or url

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE's technology appraisal process for CKD. Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system. "Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse," Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

European asset management group Aurelius has completed the acquisition of McKesson UK, marking the company's fifth completed transaction in a year. McKesson UK is the parent company of a number of healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. It comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK's success has been underpinned by its strong LloydsPharmacy brand, its customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.

Maxwellia has revealed its plans to switch some of its medicines in the self-care category from prescription-only-medicine (POM) to a pharmacy (P) medicine. After authorising the switch of Maxwellia's two brands of desogestrel contraceptive pills, Lovima and Hana, MHRA has opened a public consultation on reclassification of Aquiette (overactive bladder treatment) 2.5mg tablets manufactured by the company to be made available from pharmacies. "Maxwellia is currently looking at a number of medicines which treat a range of conditions in major public health categories that can be 'switched' from needing a prescription to being conveniently bought at a local high street or supermarket pharmacy. With its foot firmly on the accelerator it has other applications under assessment with the MHRA, including women's health products," the company stated in a recent statement. "Push to convert more prescription medicines to pharmacy medicines will firmly position pharmacists at heart of nation's public health, helping futureproof NHS," the medicine said.

Running a dental practice is no small feat! You have to ensure that both your customers are happy and your staff members too. It is easy to get caught up in the day-to-day admin and operational needs that you forget what is at the core of a successful dentist practice. How you manage your dental practice will leave lasting impressions on staff and patients, so it is important to always be trying to further yourself and improve how your practice runs. Here are 5 ways to easily improve your dental practice. IMPROVE YOUR WAITING AREA USE APPOINTMENT REMINDERS OFFER REGULAR TRAINING FOR STAFF REFINE YOUR BRAND CREATE A POSITIVE WORKING ENVIRONMENT Check Pharmacy business website for full article.

Indian drugmaker Dr Reddy's Laboratories will launch its generic version of Merck's antiviral Covid-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday (January 4). The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to 1,400 rupees ($18.77). In comparison, the treatment with Merck's pill in the United States costs $700. "Molflu is expected to be available from early next week in pharmacies throughout (India) with particular focus on states with high caseload of Covid-19," the company spokesperson said. India last week gave emergency use approval to along with two vaccines, as the country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.

With a trusted army of loyal fans on social media, the Nordic liquid iron supplement, BlueIron, is set for a refreshed look and big ambitions under a new distribution agreement. Lanes Health, the family-owned business known for its passion and expertise in manufacturing and supplying natural and herbal remedies, has acquired the distribution rights for the Finnish brand. As part of the deal, Lanes Health has been working to refresh the packaging and website, as well as developing a robust marketing campaign involving advertising, digital, social media, PR and influencer relations. A liquid iron supplement formulated with Nordic blueberries, BlueIron provides iron which is highly bioavailable and fast working. With the added benefit of a patented micro-encapsulated form of iron, it is easily absorbed and gentle on the stomach. Iron is an essential mineral used by our bodies for many health benefits, it is important for making red blood cells, transporting oxygen around the body, supporting energy metabolism, maintaining cognitive function and reducing tiredness and fatigue.

Loughborough-based generic and branded pharmaceutical manufacturer Morningside Pharmaceuticals has donated almost 60,000 packs of essential medicines to communities impacted by the war in Ukraine. The donation, which includes 1.29 million doses, was made after the company's founder and chairman, Dr Nik Kotecha OBE, spoke with the Ukrainian ambassador to the United Kingdom, Vadym Prystaiko, at a business event in London. Dr Kotecha, who was also recently appointed a deputy lieutenant of Leicestershire, said: "The heartbreaking situation in Ukraine has touched us all, and like so many people in the United Kingdom, we've been keen to do everything we can to help the victims of this terrible conflict." The large shipment of medicines has been transported in a secure and temperature controlled environment via Morningside's logistics partner to the embassy's distribution hub in Poland. From there the medicines will be supplied to hospitals, healthcare centres and patients throughout Ukraine including the regions hardest hit by the Russian invasion.

Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical Industry (ABPI). The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI. In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI. All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while also supporting economic growth for the UK.

The Medicines and Healthcare products Regulatory (MHRA) and Genomics England to launch a brand-new genetic research resource, known as a 'biobank' on Thursday (June 01) to tackle the issue of Adverse Drug Reactions (ADRs). Biobank will help to better understand how a patient's genetic makeup can impact the safety of their medicines. "The Yellow Card biobank, which will contain genetic data and patient samples, will operate alongside the MHRA's Yellow Card reporting site for suspected side effects and adverse incidents involving medicines and medical devices," said MHRA. The biobank pilot will officially begin on 1 June 2023 with participant recruitment commencing later this year, on 1 September. The sequencing of participants' genetic material will begin in Spring 2024, with initial research findings from the pilot due to be published in 2025. Genomics England will be supporting the MHRA with sequencing and storage of genetic material through use of their well-established and secure infrastructure.

British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK and Ireland stores, citing the environmental impact caused by its disposal and popularity among young people. The pharmacy retailer will discontinue selling brands like Vuse GO and Flavaah Bars, with plans to completely clear out existing stock by the end of the year, the company said in statement. Superdrug, which previously sold 1,300 single-use vapes weekly, expects a potential impact on revenue stemming from this decision. The company has not yet started selling vapes online. "This decision was made to safeguard the environment," the company said on Sept.22, highlighting the risk of fires due to improper disposal of vapes, as many of them contain lithium batteries.

Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims. GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent. GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent listed company last month, comprises consumer health assets once partly owned by GSK. The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus. The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a note.

The Royal Pharmaceutical Society (RPS) has launched a new revised RPS Professional Standards for Hospital Pharmacy Services at its annual conference held on Friday (11 November). RPS developed the standards through an extensive consultation with the profession, multidisciplinary teams and patients. They are relevant for providers of pharmacy services in acute, mental health, private, community service, prison, hospice and ambulance settings. The revised Standards contain two brand new descriptors - research, audit and quality improvement, and inclusion and wellbeing. Updates have been made to the supporting statements to ensure they reflect current practice and are fit for the future. A new assessment tool has been developed to support organisations either self-assess or peer-assess against the Standards. "For the first time the Standards apply UK wide, having gained support from Pharmacy Forum NI, alongside endorsement from The Association of Pharmacy Technicians UK and other professional groups," RPS said.

Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director. With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business. During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability. The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful acquisition by Perrigo Company plc." David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.

Well Pharmacy has announced a new partnership with RangeMe, a product discovery, sourcing and purchasing platform, as it looks to increase the diversity of products available to its customers. The independent pharmacy chain said the partnership will provide new, emerging and diverse brands increased access to its buying teams. There are already over 200,000 suppliers registered on the RangeMe platform. "We pride ourselves on being at the heart of the communities we serve and are delighted to be working with RangeMe to increase the diversity of the products we are able to offer to our customers across the UK," Reena Takhar, head of OTC & NHS buying at Well Pharmacy said. "Given the ongoing cost-of-living crisis, we're keen to do all we can to give businesses of all sizes the opportunity to connect with our buyersto allow us to offer new and interesting great value products to our customers." RangeMe helps retailers and their buying teams scale product sourcing efforts with streamlined submissions, simplified discovery tools, and the industry standard digital sell sheet.

The Royal Pharmaceutical Society (RPS) has launched a new campaign to help parents and carers in pharmacy get the support they need in the workplace as part of its inclusion and diversity work. "A lack of flexibility in employment can mean work life balance is hard to keep, ramping up the pressure even more," said RPS. The society wants to lift some of the burdens on parents and carers and challenge barriers to inclusion in the workplace. It'll challenge negative attitudes to parents and carers through a brand new guide to the microaggressions you experience in the workplace. Drop in ABCD meeting at 7pm on 05 October to contribute your ideas. It wants pharmacists to be able to choose flexible working whenever they need it. Join RPS's livestream across all its social media channels at 6.30pm on Weds 26 October to hear from two pharmacists about how to make it happen!

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

HayMax, maker of the famous organic drug-free allergen barrier balm has been awarded the 'British Made Award' for Best British Allergy Product 2022. The award celebrates businesses that work tirelessly to make their region one of the most diverse and dynamic the UK has to offer. HayMax MD and creator Max Wiseberg comments: "This award means a great deal to us. We've always been proud that our products have been manufactured in the UK. We are passionate about reducing the cost to the environment so being British-made means we keep the miles down and reduce our carbon footprint." HayMax balms are manufactured in the UK. It buys local to reduce the cost to the environment, even if it means it costs a bit more. HayMax's current pots are now made in the UK, which has been great for reducing their carbon footprint. Its tins come from London. The new pots can be recycled and re-used. The brand has now switched to using sugar cane to make its pots and has also reduced the amount of material used in the pots by just over 54%. And they have switched from the plastic labels to paper labels.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

The Association of the British Pharmaceutical Industry (ABPI) on Thursday (February 2) called for the government to scrap its plans to raise the repayment rates for drugmakers, to avoid possible setbacks in the sector. Drugmakers that are part of the government's voluntary scheme agreement, which makes branded medicines affordable for people, are required to pay a part of their drug revenue to the government. The Department of Health and Social Care plans to raise the revenue clawback rate to 27.5 per cent from 24.5 per cent. The country's ongoing attempt to raise rates is likely to send the "worst possible signal" to global investors and boardrooms, said the ABPI. "Hiking these clawbacks to such uncompetitive levels risks undermining the UK's offer to global life sciences companies," Richard Torbett, chief executive of the ABPI, said in a statement. Pharmaceuticals giants AbbVie and Eli Lilly withdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5 per cent.

The Royal Pharmaceutical Society (RPS) Scotland has launched an online pharmacy best practice hub to showcase the best practices adopted by pharmacy teams in Scotland. The brand new pharmacy best practice hub, hosted on the RPS Scotland website, went live on Thursday (August 11). RPS Scotland said: "Pharmacy teams across Scotland are undertaking fantastic work right now, in a variety of settings including community, hospital and general practice pharmacy as well as specialist settings. Many of these examples demonstrate the very best in pharmacy practice, which is supporting the profession to move further towards RPS Scotland's professional vision for the future of pharmacy, Pharmacy 2030." RPS wants to celebrate and share these examples with healthcare professionals, government, politicians, the public and potential pharmacy students to inspire people into the profession. It also provides a fantastic opportunity for pharmacy teams to share their practice with each other across the country.